A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of CJ-12420 in Patients With Non-erosive Reflux Disease
Phase of Trial: Phase III
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Tegoprazan (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Sponsors CJ HealthCare
- 02 Apr 2018 Status changed from recruiting to completed.
- 28 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
- 28 Dec 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Jun 2017.